Press Release Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial Results expected in May 2025 Last ...

NCX 470, Nicox’s lead clinical product candidate, is a novel NO-donating bimatoprost eye drop, currently in Phase 3 clinical development for the lowering of IOP in patients with open-angle ...

Each subject participated in the trial for approximately 8 days. NCX 470, Nicox's lead clinical product candidate, is a novel NO-donating bimatoprost eye drop, currently in Phase 3 clinical ...

One of the most underrated ways to get better-looking lashes is with castor oil. We tapped two dermatologists and a ...

NCX 470 0.1% achieved an intraocular pressure of less than or equal to 18 mmHg compared to latanoprost 0.005% in the trial.

So there really is an active ingredient, but again, they haven’t been evaluated for their efficacy or safety.” But not all ...

This product contains Bimatoprost, a medication used to treat ocular conditions such as glaucoma. It moved into the cosmetics space once people realised it also increased the size and length of ...

Press ReleaseNicox Extends Cash Runway into Q4 2025 Flexible equity financing line with Vester Finance of up to 10,000,000 shares over 24 monthsImmediate upfront payment from Vester Finance of €0.5 ...

Nicox Presents New Analysis from the NCX 470 Mont Blanc Trial and Provides Development Update More patients on NCX 470 achieve an intraocular pressure (IOP) of less than or equal to 18 mmHg compared ...